How to Stop Bleeding in Ulcerative Colitis

Bleeding from ulcerative colitis stops when the inflammation driving it is brought under control, and the approach depends heavily on how severe the flare is. For mild disease, anti-inflammatory medications taken by mouth or rectally can resolve bleeding within weeks. For moderate to severe flares, stronger drugs, including corticosteroids, biologics, and newer small-molecule therapies, are used to shut down the immune response attacking the colon lining. In rare cases of massive, life-threatening hemorrhage, surgery may be the only option. The key insight is that rectal bleeding in UC is almost never treated as a “bleeding problem” the way a stomach ulcer bleed might be; it is treated as an inflammation problem.

Why Ulcerative Colitis Causes Bleeding

The bleeding you see with ulcerative colitis comes from the inner lining of the colon. In UC, the immune system attacks the mucosa, the thin tissue that lines the large intestine. That attack creates ulcers, erosions, and tissue that is swollen and fragile. Blood vessels near the surface become exposed and easily disrupted. Every bowel movement can irritate these raw areas, which is why bloody stool and mucus are hallmark symptoms. The severity of bleeding tracks closely with how inflamed the colon is. Someone with mild proctitis (inflammation limited to the rectum) might see streaks of blood on toilet paper, while someone in a severe flare can lose enough blood to need transfusions.

Because the bleeding originates from widespread mucosal inflammation rather than a single ruptured vessel, the treatment strategy focuses on calming that inflammation. Once the mucosa begins to heal, the bleeding resolves. This is different from, say, a bleeding peptic ulcer where a gastroenterologist can cauterize one spot and stop the hemorrhage. In UC, the “wound” can span the entire colon.

Mesalamine for Mild to Moderate Flares

For people with mild to moderate UC, mesalamine (also called 5-ASA) is the standard first treatment. It works as a topical anti-inflammatory directly on the colon lining. In mild to moderate active disease, mesalamine produces response rates between about 40% and 70%, with remission rates of roughly 15% to 20%. Higher doses work better: people treated with 4.8 grams per day are significantly more likely to improve by week six compared to those on 2.4 grams per day. For maintenance therapy once bleeding has stopped, the lower dose of 2.4 grams per day is usually sufficient.¹

If your UC is limited to the left side of the colon or the rectum, rectal formulations like suppositories and enemas tend to work better than oral pills alone, because they deliver the drug directly to the inflamed tissue. Combining oral and rectal mesalamine often gives the best results for left-sided disease. The effect is not instant; you should expect to see bleeding taper over two to four weeks, sometimes longer. If bleeding persists beyond six to eight weeks on optimized mesalamine therapy, your gastroenterologist will likely escalate treatment.

Corticosteroids for Stronger Flares

When mesalamine is not enough, or when a flare is moderate to severe from the start, corticosteroids become the next step. Oral prednisone is the classic choice for outpatient management, while intravenous steroids like methylprednisolone or hydrocortisone are used in the hospital for acute severe UC. Steroids are powerful and broad-acting, suppressing the overactive immune response quickly. Most people notice improvement in bleeding within several days of starting intravenous steroids.

The catch is that steroids are not a long-term solution. They come with significant side effects when used for extended periods, including bone thinning, weight gain, high blood sugar, mood changes, and increased infection risk. They are also poor at maintaining remission. The role of steroids in UC is to act as a bridge: suppress the acute inflammation quickly, then transition to a maintenance therapy that can keep things under control without the side-effect burden. If bleeding does not respond to several days of intravenous steroids, the flare is classified as “steroid-refractory,” and rescue therapies are needed.

Biologic Therapies

Biologic medications have transformed UC treatment over the past two decades. These are antibody-based drugs that target specific molecules in the inflammatory cascade. The most established class for UC is anti-TNF therapy, with infliximab being the most widely used. In patients with refractory UC, infliximab has shown marked improvement clinically, colonoscopically, and histologically after even a single infusion.² For people who have failed steroids and mesalamine, infliximab can stop bleeding and induce mucosal healing where other drugs could not.

Vedolizumab is a gut-selective biologic that works differently: instead of blocking TNF throughout the body, it prevents immune cells from migrating specifically into the gut lining. This targeted approach means fewer systemic side effects. In people who have never tried a biologic before, vedolizumab can produce early improvement: about 22% of biologic-naive UC patients achieved a composite score of zero rectal bleeding and near-normal stool frequency as early as week two, compared to roughly 7% on placebo.³ By week 26, real-world data suggest that about two-thirds of UC patients on vedolizumab achieve resolution of rectal bleeding.⁴

The trade-off with biologics is time. They take weeks to reach full effect, which is fine for a moderate flare being managed on an outpatient basis but can be too slow for someone bleeding heavily in the hospital. Infliximab tends to act faster than vedolizumab, which is one reason it is preferred in acute severe cases.

JAK Inhibitors and Their Rapid Onset

One of the most exciting developments for UC bleeding is the emergence of JAK inhibitors, specifically tofacitinib and upadacitinib. These are oral pills rather than infusions, and their standout feature is speed. Tofacitinib reaches peak blood levels within about an hour and can produce clinical improvements as early as day three. Upadacitinib may work even faster, with significant improvement in stool frequency and rectal bleeding observed as early as 24 hours after the first dose.⁵

In a trial of upadacitinib, patients showed significant improvements across all UC symptoms between days one and three compared to placebo, and those improvements held through day 14. Roughly three-quarters of patients on the drug achieved a greater than 50% drop in their blood inflammatory marker (C-reactive protein).⁶ When comparing the two JAK inhibitors head-to-head in acute severe UC, upadacitinib showed higher response rates in the first week (about 84% versus 54% for tofacitinib), though the two drugs performed similarly by six months.⁷

This rapid onset makes JAK inhibitors attractive as rescue therapy, particularly for people who have already tried biologics. Their oral route is also a practical advantage in hospital settings where patients are acutely ill. The main safety concerns include an increased risk of infections and, at higher doses, blood clots, which your gastroenterologist will weigh against the severity of your flare.

Rescue Therapy When Steroids Fail

About a third of patients hospitalized with acute severe UC do not respond adequately to intravenous steroids. This is a dangerous situation because ongoing severe bleeding can lead to anemia, hemodynamic instability, and the need for emergency surgery. The two established rescue drugs are infliximab and cyclosporine, and they perform comparably: a meta-analysis found no significant difference between them in colectomy rates at three months or twelve months.⁸

In practice, many clinicians lean toward infliximab because it is easier to administer and has better long-term durability, meaning patients who respond to it can continue it as maintenance therapy. Cyclosporine requires careful blood-level monitoring and is typically bridged to another maintenance drug like azathioprine. For patients who have already failed a biologic, tofacitinib has emerged as an appealing rescue option because of its rapid onset.⁹ In select cases at specialized centers, sequential rescue therapy (trying a second rescue drug if the first one fails) may be considered before resorting to surgery.

When Massive Bleeding Requires Surgery

Massive rectal bleeding, meaning enough blood loss to cause hemodynamic instability or require repeated transfusions, is uncommon in UC, accounting for roughly 0.1% to 1.4% of admissions.¹⁰ But when it happens, it can be life-threatening and may require emergency colectomy, the surgical removal of all or most of the colon.

In a long-term case series of 25 patients with UC and severe hemorrhage, 22 required surgery. Subtotal colectomy, which removes the colon but preserves the rectum, was the most common procedure in emergency cases and allows for a future reconstructive operation to create an internal pouch. One important caveat: even after subtotal colectomy, there is roughly a 12% chance of continued bleeding from the remaining rectal stump.¹¹ Surgeons make the call based on how much blood the patient has lost, whether medical therapies have failed, and whether complications like toxic megacolon are present.

The threshold for surgery is not precise and requires clinical judgment. A multidisciplinary team involving gastroenterologists, surgeons, and sometimes interventional radiologists is recommended.¹² Delaying surgery when the clinical picture calls for it can increase the risk of complications and death.

Endoscopic and Radiologic Options

Unlike upper GI bleeding, where endoscopy frequently stops the hemorrhage with clips or cautery, endoscopic hemostasis plays a much smaller role in UC. The bleeding in UC is diffuse, arising from large areas of inflamed mucosa rather than a single vessel. That said, hemostatic powders, which are sprayed over bleeding tissue during colonoscopy, have shown promise for lower GI bleeding in general. A systematic review found an immediate hemostasis rate of about 96% and a seven-day rebleeding rate of roughly 20% across lower GI bleeding cases.¹³ These powders may buy time while medical therapy takes effect, but they are not a definitive treatment for UC-related bleeding.

Transcatheter arterial embolization, where an interventional radiologist threads a catheter into the artery feeding the bleeding site and blocks it, is commonly used for other types of lower GI bleeding. In UC, however, the evidence is discouraging. Case reports have described this approach as ineffective in UC patients with severe acute hemorrhage, and experts caution that colectomy should not be delayed in favor of embolization in this setting.¹⁴ There is at least one reported case of successful highly selective embolization in a UC patient, suggesting it might work in carefully selected individuals, but this remains the exception rather than the rule.¹⁵

Managing the Anemia That Comes with Chronic Bleeding

Even when bleeding is not dramatic enough to require emergency care, chronic blood loss from UC frequently leads to iron-deficiency anemia. This leaves you fatigued, short of breath, and pale. Iron supplementation is the standard treatment, but the route matters. During an active flare, the inflamed gut absorbs oral iron poorly, and some gastroenterologists worry that unabsorbed iron sitting in the colon could further irritate the mucosa. For patients in a flare or those who have side effects from oral iron (nausea, constipation, cramping), intravenous iron is the preferred approach. IV iron can be given safely even during active disease and alongside biologic therapy.¹⁶

Once UC is in remission and iron deficiency is mild, oral iron is reasonable as a first choice. The practical takeaway: if you are bleeding and anemic, do not wait until the flare resolves to address your iron levels. IV iron can go in while your other treatments are working on the inflammation.

Medications That Can Make UC Bleeding Worse

If you have UC, non-steroidal anti-inflammatory drugs like ibuprofen and naproxen deserve particular caution. NSAIDs can trigger exacerbations of ulcerative colitis, worsening both symptoms and mucosal damage.¹⁷ Case reports have documented UC relapses following NSAID use, with some patients relapsing again upon re-exposure. Even COX-2 selective inhibitors, once thought safer for the gut, have been linked to relapses in IBD.¹⁸ For pain management, acetaminophen (paracetamol) is generally considered the safer option for people with UC, though you should discuss this with your doctor.

Blood thinners (anticoagulants) are another concern. People with UC already have an elevated risk of blood clots, and severe flares treated with corticosteroids can increase that risk further. Case reports describe patients developing pulmonary embolism during acute severe UC treated with steroids, requiring anticoagulation once the GI bleeding has been clearly controlled.¹⁹ The timing of when to start or restart blood thinners in someone with active UC bleeding is a genuinely difficult clinical decision that requires balancing clotting risk against bleeding risk.

Preventing Bleeding from Coming Back

Stopping an active bleed is only half the challenge. UC is a chronic disease, and without ongoing treatment, flares recur. The goal of maintenance therapy is not just to keep symptoms away but to achieve mucosal healing, meaning the colon lining looks normal or near-normal on colonoscopy. A retrospective study found that patients who maintained endoscopic healing across two consecutive colonoscopies had only about an 11.5% risk of relapsing within a year. Among those who also had histological remission (no microscopic inflammation), the risk dropped to roughly 9.5%.²⁰

This means that even when you feel fine, sticking with your maintenance medication and following through on surveillance colonoscopies matters. The deeper the remission, the more durable it tends to be. Stopping maintenance therapy because you feel well is one of the most common reasons bleeding returns.

Hyperbaric Oxygen as an Emerging Therapy

One newer approach being studied for UC flares is hyperbaric oxygen therapy (HBOT), which involves breathing pure oxygen in a pressurized chamber. The rationale is that the inflamed colon in UC is chronically starved of oxygen, and flooding the tissue with oxygen may help reduce inflammation and promote healing.²¹

Early results are intriguing. In a phase 2B trial of hospitalized UC patients with moderate to severe flares, 55% achieved a clinical response by day three, with significant reductions in stool frequency, rectal bleeding, and inflammatory markers.²² A smaller pilot trial found that patients receiving 20 sessions showed better composite responses than those receiving 10 sessions, and clinical responders had measurably increased blood flow to the colon wall.²³ A larger randomized, sham-controlled trial is underway to confirm these findings and assess how long the benefits last. HBOT is not yet standard care for UC, but it may eventually become a useful add-on for hospitalized patients who need rapid improvement while waiting for their primary medical therapy to take hold.